Active B12 (Holotranscobalamin) Testing

Table of Contents

  1. Why "Normal" B12 May Not Be Enough
  2. The UCSF BrANCH 2025 Study
  3. What Holotranscobalamin Actually Is
  4. Why Total B12 Is Misleading
  5. The Four-Tier B12 Panel
  6. Reference Ranges and Interpretation
  7. Who Should Ask for the Active B12 Test
  8. Logistics: How to Order It, Cost, Reliability
  9. Treatment When holoTC Is Low
  10. Key Research Papers

Why "Normal" B12 May Not Be Enough

Your doctor orders a B12 level, the number comes back at 450 pmol/L, and everyone breathes a sigh of relief. "You're fine." But what if that number is giving you a false sense of security?

The standard serum B12 test measures total B12 in your blood — which sounds straightforward, but there is a catch. B12 travels in the bloodstream attached to two very different carrier proteins. One of them actually delivers B12 into your cells. The other does not. The routine test counts both together and cannot tell you which fraction you actually have.

This matters most for your brain, spinal cord, and peripheral nerves — all tissues that depend on a steady supply of usable B12 for myelin synthesis, DNA repair, and neurotransmitter metabolism. When the cell-deliverable fraction runs low, those tissues silently suffer even while your total B12 looks reassuringly normal on paper.

The test that measures only the cell-deliverable fraction is called the holotranscobalamin (holoTC) test — also marketed as the "Active B12" test. It is increasingly available through major commercial labs and has been available in Europe for over a decade. This article explains what it measures, who needs it, and what to do when the result is low.

Back to Table of Contents

The UCSF BrANCH 2025 Study

A landmark paper published by researchers at the University of California, San Francisco in early 2025 put the active B12 question squarely on the clinical map for cognitive health.

The study followed 231 cognitively healthy older adults (mean age 71) who had blood drawn for both total B12 and holotranscobalamin. Their mean total B12 was 414.8 pmol/L — comfortably above the standard clinical cutoff of 148 pmol/L. By every conventional measure, these people were "B12-sufficient."

Despite that, participants with lower active B12 (holoTC) — not lower total B12 — showed:

Total B12 did not predict these outcomes. Active B12 did. The findings suggest that the brain is sensitive to the deliverable fraction of B12, and that the standard test misses a clinically meaningful window of insufficiency in older adults who appear normal by current criteria.

The study was covered in a UCSF news release titled "Healthy vitamin B12 levels may not be enough to ward off neurological decline" (February 2025). It is a wake-up call for clinicians and patients alike: normal is not always normal.

Back to Table of Contents

What Holotranscobalamin Actually Is

To understand holoTC, you need to understand how B12 gets from your food into your cells — because the journey is surprisingly complicated.

After B12 is absorbed in the small intestine (with the help of intrinsic factor secreted by the stomach), it enters the bloodstream and immediately binds to carrier proteins. There are two:

  1. Transcobalamin II (TC II) — a transport protein that carries B12 to receptors on virtually every cell in the body. When B12 is bound to TC II, the resulting complex is called holotranscobalamin (holoTC). This is the biologically active fraction — the only form that can actually enter cells and be used.
  2. Haptocorrin (HC) — also called transcobalamin I or R-binder. Roughly 80% of circulating B12 is bound to haptocorrin. Cells do not have receptors for the haptocorrin-B12 complex. This fraction cannot enter cells and serves no known metabolic function. Its physiological role is poorly understood; it may act as a B12 reservoir or have roles in innate immunity.

The upshot: only about 20% of the B12 in your blood is "active." The standard total B12 test measures all of it — 80% inert haptocorrin-bound B12 plus 20% active holoTC — blending them into a single number that can mask a genuine shortage of the deliverable fraction.

HoloTC is a small molecule that turns over rapidly. When B12 intake or absorption drops, holoTC falls first — often within days — while total B12 may remain in the normal range for months. This makes holoTC an earlier and more sensitive marker of depleting B12 status.

Back to Table of Contents

Why Total B12 Is Misleading

There are several physiological situations in which total B12 is elevated, normal, or borderline — yet the patient is functionally B12-deficient at the cellular level:

The clinical consequence: a patient with total B12 of 300 pmol/L (technically "normal" by most lab ranges) could have holoTC of 30 pmol/L — below the deficiency threshold — and be developing subacute combined degeneration of the spinal cord while their chart notes say "B12 WNL."

Back to Table of Contents

The Four-Tier B12 Panel

No single B12 biomarker is perfect. The most complete picture comes from combining four complementary tests, each measuring a different step in the B12 supply chain:

  1. Total serum B12 — the standard screen. Catches severe deficiency. Misses functional deficiency when haptocorrin-bound B12 is disproportionately high. Still useful as the entry point.
  2. Holotranscobalamin (holoTC / Active B12) — measures the cell-deliverable fraction directly. Falls before total B12 crosses the lower limit. The best early marker of B12 depletion and the most logistically straightforward upgrade to the standard test.
  3. Methylmalonic acid (MMA) — a metabolite that accumulates when B12 inside cells is insufficient. B12 is required as a cofactor for the enzyme methylmalonyl-CoA mutase; when B12 is low, MMA builds up in blood and urine. MMA is the most cell-specific functional marker of B12 deficiency — it tells you whether the B12 that is getting into cells is actually adequate for biochemistry. Elevated MMA with normal or borderline holoTC strongly confirms intracellular deficiency.
  4. Homocysteine — another metabolite that rises when B12 (and/or folate) is insufficient. B12 is needed (along with folate and B6) to convert homocysteine to methionine. Elevated homocysteine raises cardiovascular and neurological risk independently. However, homocysteine is less specific for B12 deficiency than MMA because it also rises with folate deficiency, renal impairment, and certain genetic polymorphisms (e.g., MTHFR).

In practice, the most useful upgrade from the standard test is adding holoTC + MMA. Together, they give you both the supply (holoTC) and the functional consequence (MMA). Homocysteine adds value when cardiovascular risk stratification is also desired.

Back to Table of Contents

Reference Ranges and Interpretation

Reference ranges vary somewhat by laboratory, but the following are widely used in clinical research and European clinical practice:

Holotranscobalamin (holoTC)

Methylmalonic Acid (MMA)

Total Serum B12 (for context)

How the pieces fit together

Back to Table of Contents

Who Should Ask for the Active B12 Test

Not everyone needs holoTC testing. It adds the most value when there is a reason to doubt that the standard total B12 is telling the whole story. Consider asking your doctor about adding holoTC (and ideally MMA) if any of the following apply:

Back to Table of Contents

Logistics: How to Order It, Cost, Reliability

Lab names and ordering

The active B12 test is available through the two largest US commercial labs:

In the UK and much of Europe, holoTC is part of routine B12 assessment and is widely available through the NHS and private labs. The Abbott ARCHITECT holoTC assay is the most commonly used automated platform worldwide.

Self-pay cost

Without insurance, holoTC typically runs $30–$90 through direct-to-consumer lab services (e.g., Ulta Lab Tests, Walk-In Lab, LabCorp Patient). Adding MMA brings the self-pay total to roughly $60–$140, depending on the platform. Both tests are often covered by insurance when ordered by a physician for an appropriate indication (B12 deficiency workup, neurological symptoms, bariatric post-op monitoring).

Fasting requirements

Fasting is NOT required for holoTC or MMA. You can eat and drink normally before the draw. This is a practical advantage over many metabolic panels.

Sample stability and timing

HoloTC is stable in serum for up to 48 hours at 4°C and can be frozen for longer storage. Samples do not need to be processed immediately, making the test reliable even at labs that batch-ship specimens. MMA samples are also stable at refrigerator temperature for 24–48 hours.

If you are currently taking B12 supplements, do not stop them before testing — results on supplementation are clinically meaningful (and stopping could cause harm). Just note your supplement dose on the lab requisition.

Reliability and assay variability

The Abbott ARCHITECT automated immunoassay for holoTC has a coefficient of variation below 5% and good agreement across labs using the same platform. However, results from different lab platforms are not always directly comparable — if tracking over time, try to use the same lab. The MMA assay by tandem mass spectrometry (LC-MS/MS) is highly accurate and widely standardized.

Back to Table of Contents

Treatment When holoTC Is Low

A low holoTC (below 35 pmol/L, or 35–50 pmol/L with elevated MMA) calls for B12 repletion. The route and dose depend on why the level is low.

When absorption is intact

If malabsorption is not the cause (dietary deficiency, increased demand), high-dose oral B12 is effective and convenient:

When absorption is impaired

Pernicious anemia, severe atrophic gastritis, or post-bariatric anatomy require bypassing gut absorption entirely:

Monitoring after treatment

Recheck holoTC and MMA at 8–12 weeks after starting therapy. This timeframe allows for meaningful cellular repletion and metabolic normalization. Total B12 will rise quickly (often within 2–4 weeks) and is not the best endpoint. Normalization of MMA confirms that cells are receiving adequate B12. HoloTC rising above 70 pmol/L confirms adequate delivery.

If MMA remains elevated at 12 weeks despite high-dose oral supplementation, suspect ongoing malabsorption and transition to IM therapy.

Neurological symptoms

If neurological symptoms are present (numbness, balance issues, cognitive slowing), do not delay treatment while awaiting test results. Treat empirically and confirm with follow-up labs. Neurological injury from B12 deficiency can be partially or fully reversible if caught early, but becomes permanent if prolonged. Earlier is always better.

Back to Table of Contents

Key Research Papers

  1. UCSF BrANCH Study Summary (Feb 2025) — "Healthy vitamin B12 levels may not be enough to ward off neurological decline." University of California, San Francisco news release covering the BrANCH cohort study (n=231, mean age 71) showing lower active B12 — not total B12 — predicted slower processing speed and greater white-matter lesion burden on MRI.
    UCSF BrANCH study summary, Feb 2025
  2. Smith AD et al. "Vitamin B12 and Cognitive Decline." Annual Review of Nutrition 2018; 38:1–26. Reviews the relationship between B12 biomarkers — including holoTC and MMA — and cognitive aging, dementia, and brain atrophy. PMID: 29852087
  3. Refsum H et al. "Holotranscobalamin and total B12 for cobalamin status: a randomized placebo-controlled study." American Journal of Clinical Nutrition 2011; 94(4):1066–1073. Demonstrates that holoTC responds more rapidly than total B12 to changes in B12 intake, supporting its role as a first marker of depletion. PMID: 21795441
  4. Heil SG et al. "Holotranscobalamin as a marker for cobalamin status: comparison with other cobalamin markers." Clinical Chemistry and Laboratory Medicine 2012; 50(5):845–852. Head-to-head comparison of holoTC, total B12, MMA, and homocysteine as diagnostic markers in a clinical population. PMID: 22962221
  5. Hannibal L et al. "Biomarkers of vitamin B12 status in serum and cerebrospinal fluid in early diagnosis of central nervous system disease." Frontiers in Molecular Biosciences 2016; 3:7. Examines how B12 biomarkers including holoTC perform in diagnosing neurological B12 deficiency. PMID: 27446930
  6. Allen LH et al. "Biomarkers of nutrition for development (BOND): vitamin B-12 review." Journal of Nutrition 2018; 148(Suppl 4):1995S–2027S. Comprehensive evidence review of all B12 biomarkers across the lifespan; recommends holoTC plus MMA as the optimal assessment strategy. PMID: 30247595
  7. Devalia V et al. "Guidelines for the diagnosis and treatment of cobalamin and folate disorders." British Journal of Haematology 2014; 166(4):496–513. UK national guidelines covering indications for holoTC testing, interpretation, and treatment protocols for pernicious anemia and other causes of B12 deficiency. PMID: 24942828
  8. Carmel R. "Diagnosis and management of clinical and subclinical cobalamin deficiencies: why controversies persist in the age of sensitive metabolic testing." Current Hematology Reports 2012; 11(2):81–90. Discusses why subclinical deficiency remains underdiagnosed and how functional markers like MMA and holoTC change clinical decision-making. PMID: 22535597
  9. Stabler SP. "Clinical practice. Vitamin B12 deficiency." New England Journal of Medicine 2013; 368(2):149–160. The definitive NEJM clinical practice review covering epidemiology, pathophysiology, diagnosis (including MMA and holoTC), and management of B12 deficiency across clinical settings. PMID: 23323902
  10. Green R et al. "Vitamin B12 deficiency." Nature Reviews Disease Primers 2017; 3:17040. Authoritative primer on the full spectrum of B12 deficiency — from biochemistry to brain imaging — including a discussion of why standard serum B12 fails to capture subclinical deficiency and what better biomarkers look like. PMID: 28660890
  11. Herrmann W, Obeid R. "Holotranscobalamin — an early marker of cobalamin malabsorption." European Journal of Clinical Investigation 2003; 33(11):983–988. Early validation of holoTC as the first serum marker to fall during experimentally induced B12 depletion — foundational work establishing its role as a "first marker." PMID: 14636287

Live PubMed Searches

  1. Holotranscobalamin active B12
  2. HoloTC cognitive decline
  3. Methylmalonic acid B12 deficiency
  4. Vitamin B12 deficiency biomarkers
  5. B12 white matter lesions MRI
  6. Pernicious anemia cobalamin treatment

Back to Table of Contents

Connections

Back to Table of Contents